On December 09, 2024 NeoGenomics, Inc. (NASDAQ: NEO), a leading oncology testing services company, reported the company will share its latest research on hematologic malignancies and the prognostic effects of microenvironment signatures in primary central nervous system (CNS) lymphoma at the 2024 American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting, booth #2347, in San Diego, December 7-10 (Press release, NeoGenomics Laboratories, DEC 9, 2024, View Source [SID1234648956]). The company will also feature its robust hematological oncology solutions, including COMPASS, AML Express, and AML MRD Flow Panel.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"Our research at ASH (Free ASH Whitepaper) demonstrates that NeoGenomics continues to advance its leadership position in precision diagnostics for hematologic cancers," said Warren Stone, Chief Commercial Officer of NeoGenomics. "Through our collaboration with Duke University and the innovative work of our scientific team, we are uncovering critical insights into the genetic and microenvironmental factors that influence patient outcomes. These studies can potentially refine prognostic tools, align diagnostics with clinical guidelines, and ultimately improve therapeutic decision-making—enhancing care for patients battling blood cancer."
At the meeting, NeoGenomics will present a poster:
Neuronal-Glial and Immune Microenvironment Signatures Show Prognostic Effects in Primary CNS Lymphoma
Monday, December 9 at 6-8 p.m. PST
This study explores the prognostic effects of neuronal-glial and immune microenvironment signatures in primary central nervous system lymphoma. Through advanced multiplexing techniques, researchers have identified distinct microenvironment patterns with potential implications for predicting patient outcomes.
In addition to the poster, NeoGenomics’ two abstracts were recently published in the Blood supplement and archived on the ASH (Free ASH Whitepaper) and Blood abstracts site:
Genetic Insights into Myeloid Malignancies: A Comparative Analysis of NCCN Guidelines, the WHO Classification, and the ICC System
This study offers a comprehensive analysis of genetic insights into myeloid malignancies, comparing recommendations from major clinical guidelines and classifications, including the NCCN, WHO, and ICC systems.
A Prevalence Study of Gene Fusions in 2,958 Acute Myeloid Leukemia Patients from the Community Using FISH and NGS Testing
This prevalence study evaluates gene fusion occurrences in nearly 3,000 AML patients from community settings and utilizes FISH and NGS testing to uncover critical insights for diagnostic and therapeutic decision-making.
For more information about NeoGenomics’ research and presentations at ASH (Free ASH Whitepaper) 2024, visit www.neogenomics.com.